共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
Haushalter K Murad EJ Dabade TS Rowell R Pearce DJ Feldman SR 《The Journal of dermatological treatment》2012,23(6):400-403
Abstract Objectives: Clinical experience favors low doses of acitretin to reduce adverse events but still maintain efficacy. We revisited the pivotal acitretin trials to compare the efficacy of high- versus low-dose acitretin. Materials and Methods: We analyzed data from two large randomized trials which had an 8-week, double-blinded (DB), placebo-controlled phase followed by a 16-week open-label (OL) phase. During the DB phase, patients received placebo, 10, 25, 50, or 75 mg of acitretin daily. Dose adjustment was allowed during the OL phase, during which high-dose treatment was defined as approximately 50 mg/day and low-dose as approximately 25 mg/day. Primary end points were improvement of psoriasis based on investigator static global assessment (ISGA) and reduction in affected body surface area (BSA). Results: At the end of the OL phase (week 24), treatment success rates were similar among all groups (29%-33%) - with the exception of the group receiving low-dose treatment for both DB and OL phases (47% success). Decrease in BSA was also highest in this group (73% vs. 28% to 54%). Conclusion: Individualization of acitretin dosing is crucial to minimize side effects and should lead to improved adherence and efficacy. This analysis supports the utility of low-dose acitretin for psoriasis over extended treatment periods. 相似文献
3.
目的:评价长疗程应用英夫利西单抗治疗关节病型银屑病的临床疗效。方法:随访分析2016年11月至2018年11月就诊于中国人民解放军总医院皮肤科接受英夫利西单抗治疗的关节病型银屑病患者。观察第2周、6周以及此后每间隔8周用药后的关节症状及皮损改善情况以及肿瘤坏死因子-α(TNF-α)等指标的变化。结果:8例患者用药疗程满30周,纳入数据分析, 其中5例满46周。LSD法显示,治疗后患者肿胀关节数(0周VS 30周:t=6.939,P<0.001;0周VS 46周:t=3.822,P=0.019)、压痛关节数(0周VS 30周:t=5.353,P=0.001;0周VS 46周:t=3.132,P=0.035)明显减少,PASI值在第30周时下降最明显(0周VS 30周:t=3.742,P=0.007), TNF-α水平在第22周最高(0周VS 22周:t=3.569,P=0.009),超过22周后逐渐降低(30周VS 46周:t=4.104,P=0.009)。 结论:英夫利西单抗能够显著改善关节病型银屑病患者的关节症状和皮损,但长疗程应用时疗效呈降低趋势。 相似文献
4.
窄谱中波紫外线治疗寻常性银屑病的疗效观察 总被引:6,自引:2,他引:4
我们采用窄谱中波紫外线(NB-UVB)治疗72例寻常性银屑病患者,同时观察其中20例患者在光疗中皮损的组织病理及Ki-67、CD3表达情况. 相似文献
5.
目的:评价司库奇尤单抗治疗银屑病的疗效和安全性。方法:选取中重度斑块状银屑病患者及泛发性脓疱型银屑病患者,给予司库奇尤单抗,300 mg/次,0~4周每周一次,后每4周一次,并分别于治疗前、1周后、4周后、8周后记录斑块状银屑病患者的银屑病皮损面积和严重度指数(PASI)、泛发性银屑病患者银屑病症状量表(PSS)评分。结果:共治疗6例斑块状银屑病和1例脓疱型银屑病患者,所选的患者均接受至少8周的司库奇尤单抗治疗,起效时间为(1.6±0.73)天;治疗4周时,6例斑块状银屑病患者中全部达到PASI 75,3例达到PASI 90;脓疱型患者PSS评分为2。治疗8周时6例斑块状银屑病患者均达到PASI 100;脓疱型患者PSS评分为0。所有患者治疗期间均未出现严重的药物不良反应。结论:司库奇尤单抗治疗中重度银屑病起效迅速,疗效显著,不良反应少。 相似文献
6.
The efficacy of orally administered mycophenolic acid (MPA), an inhibitor of guanosine monophosphate (GMP) synthesis, for the treatment of psoriasis, was studied in a double-blind fashion. Of twenty-one patients completing the study period, ten of eleven patients treated with MPA had a greater than 25% decrease in severity score compared with only two of ten patients treated with placebo. The placebo group had a slight increase in severity score compared to almost 50% reduction in the average severity score of the MPA-treated group. After termination of the double-blind portion of the study, the placebo group was treated with MPA and showed a 60% decrease in severity score. Adverse effects encountered included anorexia, nausea, vomiting, and diarrhea. One patient had an uncomplicated episode of herpes zoster. Other than a mild decrease hemoglobin, no hematologic toxicity was noted. 相似文献
7.
8.
Luis Miguel Taveira Cristina Gonçalves António Paiva Manuela Selores Madalena Sanches António Massa 《Journal of the European Academy of Dermatology and Venereology》1997,9(3):266-268
A patient presenting with erythrodermal symptoms was diagnosed as having psoriatic erythroderma and chronic myeloid leukaemia. Both pathological conditions were effectively controlled with hydroxyurea within 9 months after diagnosis, without occurrence of adverse reactions or intolerance to therapy. 相似文献
9.
10.
银屑病作为一种反复发作的皮肤病,严重影响患者的生活质量[1]。皮肤病的辅助治疗越来越引起皮肤科医师的重视[2]。为探讨薇诺娜柔润保湿霜对寻常性银屑病的辅助作用,我们对门诊银屑病患者用窄谱中波紫外线(UVB)联合该护肤品观察其效果以及对皮肤生理指标的影响…… 相似文献
11.
银屑病是一种多基因遗传和环境相互作用下,主要由细胞免疫异常介导的慢性炎症性增生性皮肤病,其确切的发病机制尚未完全清楚.目前认为,白细胞介素17细胞因子对角质形成细胞的增生及异常激活十分重要,是银屑病发病机制中的关键环节.新研发的3种针对白细胞介素17通路的生物制剂已应用于银屑病的临床治疗或试验,包括直接拮抗白细胞介素17A的苏金单抗(secukinumab)、ixekizumab及通过拮抗白细胞介素17RA,从而抑制白细胞介素17下游信号分子通路的brodalumab.其治疗寻常性银屑病及关节病性银屑病的有效性和安全性在临床试验中得到肯定,给银屑病患者带来新的治疗选择,但其安全性仍需长远评价. 相似文献
12.
目的:评价沙利度胺治疗关节病型银屑病的临床疗效以及对患者外周血中VEGF水平的影响。方法:30例关节病型银屑病患者口服沙利度胺治疗,150mg,每日1 次,疗程 12周;采用PASI评分标准及关节症状评分评价疗效。采用酶联免疫吸附试验(ELISA)测定患者治疗前后血清VEGF水平。结果:患者治疗后皮损和关节炎均较治疗前得到明显改善;血清中VEGF水平治疗后为(578.38±169.05) pg/L较治疗前(1045.56±289.28pg/L)明显下降。结论:沙利度胺治疗关节病型银屑病安全有效,其作用机制可能与抑制患者血浆VEGF有关。 相似文献
13.
Mitsuha Hayashi Yoshinori Umezawa Osamu Fukuchi Toshihiro Ito Hidehisa Saeki Hidemi Nakagawa 《The Journal of dermatology》2014,41(11):974-980
The ratio of the elderly among psoriasis patients has been increasing. However, satisfactory long‐term management of psoriasis for the elderly is challenging because of the more frequent presence of comorbidities, and the higher risk of adverse events from systemic therapeutic agents than younger patients. The use of ustekinumab (UST) appears to be an appropriate systemic treatment because it is considered less likely to cause adverse events than other systemic treatments, as well as necessitating fewer hospital visits. Our retrospective study aimed to evaluate the efficacy and safety profile of UST in elderly patients with psoriasis. The study included 24 patients aged over 65 years (range, 65–88 years; mean, 73.1 years) with moderate to severe plaque psoriasis with impaired quality of life. Efficacy and safety were assessed over a 1‐year period using the Psoriasis Area and Severity Index (PASI) and the Dermatology Live Quality Index (DLQI). The efficacy was evaluated by the proportion of subjects who achieved ≥75% reduction in PASI score (PASI 75). PASI 75 responses were 56.5% at week 16, 59.1% at week 28, and 60.0% at week 52. None of the patients developed any serious infection during the 1‐year treatment. The mean DLQI score at weeks 0, 16, 28, and 52 was 7.8 ± 6.0, 2.5 ± 3.4, 1.4 ± 1.7, and 1.2 ± 1.7, respectively. UST showed sufficient efficacy for elderly patients with psoriasis without any serious infection over the 1‐year treatment. Our results suggest that UST is the preferable agent for the treatment of elderly patients with psoriasis. 相似文献
14.
目的:评价Secukinumab治疗成人中重度银屑病的疗效和安全性。方法:计算机检索PubMed、EMBASE、Cochrane图书馆、中国知网、维普期刊数据库、万方医学数据库、中国生物医学文献数据库有关Secukinumab治疗成人中重度银屑病的随机对照试验文献,时间为数据库建库时间至2017年2月,由两名独立的研究员对纳入的文献进行质量评价,用RevMan 5.3软件进行Meta分析。结果:分析共纳入7篇文献、3474例成人中重度银屑病患者。Meta分析结果显示,300 mg Secukinumab治疗组中PASI积分下降75%、90%和100%的患者例数和研究者全面评估(IGA)分数为0或1的患者例数高于150 mg Secukinumab治疗组及安慰剂组,差异均有统计学意义(P0.00001)。300 mg和150 mg Secukinumab治疗组中患者不良反应发生率明显高于安慰剂组,但300 mg Secukinumab治疗组和150mg Secukinumab治疗组间不良反应发生率差异无统计学意义。结论:300 mg Secukinumab治疗中重度银屑病疗效明显优于150 mg Secukinumab,不良反应发生率无明显差异。 相似文献
15.
Erceg A Bovenschen HJ van de Kerkhof PC Seyger MM 《The British journal of dermatology》2006,155(1):110-114
BACKGROUND: Localized chronic plaque psoriasis, resistant to local therapy, may be very hard to treat. The treatment of these lesions with a pulsed dye laser (PDL) has been described before, but a comparative study between the PDL and a potent topical treatment has never been performed. OBJECTIVES: To compare the efficacy of the PDL in the treatment of localized, recalcitrant plaque psoriasis with a potent topical therapy, using calcipotriol/betamethasone dipropionate (Dovobet) as an active comparator. METHODS: Eight patients with psoriasis were treated with both PDL (585 nm) and calcipotriol/betamethasone dipropionate in an open, intrapatient, left-right comparison. A plaque severity score (sum score) and photographs were used to document the course of therapy. Patients reported pain on a visual analogue scale. RESULTS: Both treatments were well tolerated, although one patient left the study due to post-PDL treatment pain. A significant difference in the sum score 12 weeks after treatment was seen in favour of the PDL (62% vs. 19% reduction; P<0.05). Scores for erythema declined significantly at week 12 in both the PDL and the calcipotriol/betamethasone dipropionate group (P<0.001). Induration and desquamation scores were significantly reduced at week 12 in the PDL group, without a statistically significant reduction in calcipotriol/betamethasone-treated lesions. The pain scores declined with progressive PDL treatments, although not statistically significantly. CONCLUSIONS: PDL treatment might be considered for the treatment of localized, recalcitrant plaque psoriasis, when other topical therapies have failed. 相似文献
16.
复方丙酸氯倍他索软膏治疗寻常性银屑病临床疗效观察 总被引:5,自引:0,他引:5
目的:观察复方丙酸氯倍他索软膏治疗寻常性银屑病的疗效和安全性。方法:将入组的360例寻常性银屑病患者分为治疗组(复方丙酸氯倍他索软膏组120例)、对照1组(0.02%丙酸氯倍他索霜组120例)和对照2组(0.05%全反式维A酸霜组120例),采用多中心、随机双盲、平行对照的方法对寻常性银屑病患者连续用药4周。结果:3组患者的痊愈率分别为48.33%、18.33%和3.48%,有效率分别为92.50%、50.83%和31.30%。组间比较(试验组与对照1组比较,试验组与对照2组比较)显示,痊愈率和有效率差异均有显著性(P<0.01)。试验组和对照1组的不良反应发生率较轻微,对照2组不良反应发生率为11.67%,有3例因不良反应较重中途停止治疗。结论:复方丙酸氯倍他索软膏是一种安全有效的治疗寻常性银屑病的外用药,其疗效优于单用丙酸氯倍他索霜或全反式维A酸霜。 相似文献
17.
18.
In 10 in-patients with chronic plaque psoriasis, the antipsoriatic effect of MC903, a new synthetic analogue of vitamin D was evaluated. In each patient two symmetrical located psoriatic plaques were selected for the study. Topical treatment with MC903 cream (containing 1.2 mg MC903 per g cream) was compared with placebo cream in a double-blind, controlled, left-right, randomized way during 6 weeks of therapy. Compared with baseline, the clinical (erythema, scaling and infiltration) improvement was significant after 1 week of therapy with MC903 cream, while lateral comparison showed MC903 cream significantly better than cream base after 4 weeks of therapy (p less than 0.05). Measurements of skin blood flow by the laser Doppler technique in evaluating the disease activity was not superior to the clinical assessments. In 3 patients the psoriatic lesions treated with MC903 cream cleared completely during 6 weeks of therapy. No essential adverse reactions were observed. MC903 has a potent effect on cell proliferation and cell differentiation, but has minimal effect on calcium metabolism. It is concluded that this synthetic vitamin D analogue is potentially useful in the treatment of psoriasis. 相似文献
19.
李洪武 《实用皮肤病学杂志》2010,3(4):209-211
目的观察地蒽酚蜡棒短程接触疗法联合窄谱中波紫外线(NB-UVB)治疗寻常型斑块状银屑病的疗效。方法 143例寻常型斑块状银屑病随机分为治疗组(地蒽酚蜡棒短程接触疗法联合NB-UVB组)49例,对照1组(地蒽酚蜡棒组)48例和对照2组(NB-UVB组)46例,连续治疗8周。结果 3组患者的基本治愈率分别为61.22%、39.58%和39.13%,总有效率分别为91.84%、77.08%和76.09%。治疗组分别与对照1组、对照2组比较,组间基本治愈率和总有效率均有显著性差异(P0.05)。结论地蒽酚蜡棒联合NB-UVB治疗寻常型斑块状银屑病疗效优于单用地蒽酚蜡棒或单用NB-UVB组。 相似文献